Abeona Therapeutics (NASDAQ: ABEO) revenue
Abeona Therapeutics reported revenue of $5.8m for fiscal 2025, 37.1% more than in fiscal 2024 ($4.2m). Since fiscal 2016 its revenue has grown by 554.7%, an average growth of 23.2% a year.
Abeona Therapeutics has grown its revenue for 3 years in a row, and its best year of the last 9 was fiscal 2020. The biggest drop was in fiscal 2021, −70.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $5.8m | +37.1% | −$89.4m | −1,536.9% |
| 2024 | $4.2m | +21.3% | −$64.2m | −1,512.3% |
| 2023 | $3.5m | +147.5% | −$47.1m | −1,346.7% |
| 2022 | $1.4m | −52.9% | −$50.9m | −3,600.8% |
| 2021 | $3.0m | −70.0% | −$89.8m | −2,994.5% |
| 2020 | $10.0m | — | −$81.4m | −814.2% |
| 2018 | $3.0m | +258.2% | −$58.2m | −1,940.2% |
| 2017 | $0.8m | −5.8% | −$27.8m | −3,325.7% |
| 2016 | $0.9m | — | −$23.9m | −2,686.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Abeona Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Abeona Therapeutics ranks 380th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Abeona Therapeutics, 37.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 378th | Immunome | $6.9m | −23.2% |
| 379th | Korro Bio | $6.4m | 181.5% |
| 380th | Abeona Therapeutics | $5.8m | 37.1% |
| 381st | Lucid Diagnostics | $4.7m | 8.3% |
| 382nd | Prime Medicine | $4.6m | 55.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Abeona Therapeutics
- How much revenue did Abeona Therapeutics make in fiscal 2025?
- Abeona Therapeutics reported revenue of $5.8m for fiscal 2025, compared with $4.2m in fiscal 2024.
- How much has the revenue of Abeona Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $0.9m to $5.8m: 554.7% more, an average growth of 23.2% a year.
- What was the best year for revenue at Abeona Therapeutics?
- Of its last 9 fiscal years, fiscal 2020, with $10.0m.
- Where does Abeona Therapeutics rank in its sector by revenue?
- It ranks 380th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Abeona Therapeutics come from?
- From the annual report (Form 10-K) that Abeona Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Abeona Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2018 · 2017 · 2016. More on Abeona Therapeutics: the Abeona Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.